公开(公告)号：US20210386764A1

公开(公告)日：2021-12-16

申请号：US17290912

申请日：2019-11-08

Applicant: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA

Inventor： Hanjun Wang ,  Dong Wang ,  Thomas Nicholas ,  Michael Lankhorst ,  Steven Lisco ,  Irving Zucker ,  Lie Gao ,  Juan Hong

IPC: A61K31/65 ,  A61K31/573 ,  A61P9/14 ,  A61K9/00 ,  A61K45/06

Abstract: Compositions and methods for the treatment of peripheral artery disease and cardiopulmonary diseases or disorders are provided. In accordance with the instant invention, methods of inhibiting, treating, and/or preventing peripheral artery disease or symptoms associated therewith are provided. In a particular embodiment, the methods inhibit, treat, and/or prevent claudication associated with peripheral artery disease.

公开(公告)号：US12138274B2

公开(公告)日：2024-11-12

申请号：US17290912

申请日：2019-11-08

Applicant: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA

Inventor： Hanjun Wang ,  Dong Wang ,  Thomas Nicholas ,  Michael Lankhorst ,  Steven Lisco ,  Irving Zucker ,  Lie Gao ,  Juan Hong

IPC: A61K31/65 ,  A61K9/00 ,  A61K31/573 ,  A61K45/06 ,  A61P9/14

Abstract: Compositions and methods for the treatment of peripheral artery disease and cardiopulmonary diseases or disorders are provided. In accordance with the instant invention, methods of inhibiting, treating, and/or preventing peripheral artery disease or symptoms associated therewith are provided. In a particular embodiment, the methods inhibit, treat, and/or prevent claudication associated with peripheral artery disease.

公开(公告)号：US20180140544A1

公开(公告)日：2018-05-24

申请号：US15668063

申请日：2017-08-03

Applicant: Board of Regents of the University of Nebraska

Inventor： Irving H. Zucker ,  Hanjun Wang

IPC: A61K9/00 ,  A61K31/357

CPC classification number: A61K9/0019 ,  A61K9/0085 ,  A61K31/357

Abstract: There is disclosed a method for administration of a formulation of resiniferatoxin (RTX) to provide cardiac sympathetic afferent denervation when applied in an amount and concentration sufficient to chemically denervate vanilloid 1 receptor (TRPV1)-expressing CSAR (cardiac sympathetic afferent reflex) afferents. There is further disclosed a method for treating heart failure or hypertension and its related indications selected from the group consisting of increased sympatho-excitation, cardiac hypertrophy, increased left ventricular end diastolic pressure (LVEDP), lung edema, and combinations thereof, comprising administering an effective amount of RTX directly to a tissue site selected from the group consisting of epicardium, a T1-T4 dorsal root ganglion and intrathecally to the T1-T4 region of the spinal column.

公开(公告)号：US20250082605A1

公开(公告)日：2025-03-13

申请号：US18622241

申请日：2024-03-29

Applicant: Board of Regents of the University of Nebraska

Inventor： Irving H. Zucker ,  Hanjun Wang

IPC: A61K31/357 ,  A61K9/00 ,  A61K31/4468 ,  A61K45/06

Abstract: The present application provides methods for treating cardiovascular conditions. The methods can include administering a Transient Receptor Potential Vanilloid 1 (TRPV1) receptor agonist to an epidural space. The methods can be used to treat a variety of conditions such as hypertension, prehypertension, mild hypertension, severe hypertension, refractory hypertension, congestive heart failure and myocardial scarring.

公开(公告)号：US11679075B2

公开(公告)日：2023-06-20

申请号：US16911070

申请日：2020-06-24

Applicant: Board of Regents of the University of Nebraska

Inventor： Irving H. Zucker ,  Hanjun Wang

IPC: A61K31/357 ,  A61K9/00

CPC classification number: A61K9/0019 ,  A61K9/0085 ,  A61K31/357

Abstract: There is disclosed a method for administration of a formulation of resiniferatoxin (RTX) to provide cardiac sympathetic afferent denervation when applied in an amount and concentration sufficient to chemically denervate vanilloid 1 receptor (TRPV1)-expressing CSAR (cardiac sympathetic afferent reflex) afferents. There is further disclosed a method for treating heart failure or hypertension and its related indications selected from the group consisting of increased sympatho-excitation, cardiac hypertrophy, increased left ventricular end diastolic pressure (LVEDP), lung edema, and combinations thereof, comprising administering an effective amount of RTX directly to a tissue site selected from the group consisting of epicardium, a T1-T4 dorsal root ganglion and intrathecally to the T1-T4 region of the spinal column.

公开(公告)号：US20230277443A1

公开(公告)日：2023-09-07

申请号：US18197905

申请日：2023-05-16

Applicant: Board of Regents of the University of Nebraska

Inventor： Irving H. Zucker ,  Hanjun Wang

IPC: A61K9/00 ,  A61K31/357

CPC classification number: A61K9/0019 ,  A61K31/357 ,  A61K9/0085

Abstract: There is disclosed a method for administration of a formulation of resiniferatoxin (RTX) to provide cardiac sympathetic afferent denervation when applied in an amount and concentration sufficient to chemically denervate vanilloid 1 receptor (TRPV1)-expressing CSAR (cardiac sympathetic afferent reflex) afferents. There is further disclosed a method for treating heart failure or hypertension and its related indications selected from the group consisting of increased sympatho-excitation, cardiac hypertrophy, increased left ventricular end diastolic pressure (LVEDP), lung edema, and combinations thereof, comprising administering an effective amount of RTX directly to a tissue site selected from the group consisting of epicardium, a T1-T4 dorsal root ganglion and intrathecally to the T1-T4 region of the spinal column.

公开(公告)号：US20220000837A1

公开(公告)日：2022-01-06

申请号：US17375796

申请日：2021-07-14

Applicant: Board of Regents of the University of Nebraska

Inventor： Irving H. Zucker ,  Hanjun Wang

IPC: A61K31/357 ,  A61K9/00 ,  A61K45/06 ,  A61K31/4468

Abstract: The present application provides methods for treating cardiovascular conditions. The methods can include administering a Transient Receptor Potential Vanilloid 1 (TRPV1) receptor agonist to an epidural space. The methods can be used to treat a variety of conditions such as hypertension, prehypertension, mild hypertension, severe hypertension, refractory hypertension, congestive heart failure and myocardial scarring.

公开(公告)号：US20200323771A1

公开(公告)日：2020-10-15

申请号：US16911070

申请日：2020-06-24

Applicant: Board of Regents of the University of Nebraska

Inventor： Irving H. Zucker ,  Hanjun Wang

IPC: A61K9/00 ,  A61K31/357

Abstract: There is disclosed a method for administration of a formulation of resiniferatoxin (RTX) to provide cardiac sympathetic afferent denervation when applied in an amount and concentration sufficient to chemically denervate vanilloid 1 receptor (TRPV1)-expressing CSAR (cardiac sympathetic afferent reflex) afferents. There is further disclosed a method for treating heart failure or hypertension and its related indications selected from the group consisting of increased sympatho-excitation, cardiac hypertrophy, increased left ventricular end diastolic pressure (LVEDP), lung edema, and combinations thereof, comprising administering an effective amount of RTX directly to a tissue site selected from the group consisting of epicardium, a T1-T4 dorsal root ganglion and intrathecally to the T1-T4 region of the spinal column.

公开(公告)号：US10729643B2

公开(公告)日：2020-08-04

申请号：US15668063

申请日：2017-08-03

Applicant: Board of Regents of the University of Nebraska

Inventor： Irving H. Zucker ,  Hanjun Wang

IPC: A61K31/357 ,  A61K9/00

Abstract: There is disclosed a method for administration of a formulation of resiniferatoxin (RTX) to provide cardiac sympathetic afferent denervation when applied in an amount and concentration sufficient to chemically denervate vanilloid 1 receptor (TRPV1)-expressing CSAR (cardiac sympathetic afferent reflex) afferents. There is further disclosed a method for treating heart failure or hypertension and its related indications selected from the group consisting of increased sympatho-excitation, cardiac hypertrophy, increased left ventricular end diastolic pressure (LVEDP), lung edema, and combinations thereof, comprising administering an effective amount of RTX directly to a tissue site selected from the group consisting of epicardium, a T1-T4 dorsal root ganglion and intrathecally to the T1-T4 region of the spinal column.

公开(公告)号：US20170296506A1

公开(公告)日：2017-10-19

申请号：US15487263

申请日：2017-04-13

Applicant: Board of Regents of the University of Nebraska

Inventor： Irving H. Zucker ,  Hanjun Wang

IPC: A61K31/357 ,  A61K9/00 ,  A61K31/4468 ,  A61K45/06

CPC classification number: A61K31/357 ,  A61K9/0019 ,  A61K9/0085 ,  A61K31/4468 ,  A61K45/06 ,  A61K2300/00

Abstract: The present application provides methods for treating cardiovascular conditions. The methods can include administering a Transient Receptor Potential Vanilloid 1 (TRPV1) receptor agonist to an epidural space. The methods can be used to treat a variety of conditions such as hypertension, prehypertension, mild hypertension, severe hypertension, refractory hypertension, congestive heart failure and myocardial scarring.